Does the length of the columnar-lined esophagus change with time?

Diseases of the Esophagus

Volumn 20, Issue 6, 2007, Pages 497-503

  Gatenby, Piers A C ^a   Ramus, J R ^a   Caygill, C P J ^a   Watson, A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Adenocarcinoma; Barrett' sesophagus; Disease progression; Metaplasia

Indexed keywords

PROTON PUMP INHIBITOR;

ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER REGRESSION; CANCER RISK; CARCINOGENESIS; COLUMNAR EPITHELIUM; DISEASE SURVEILLANCE; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS MUCOSA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; METAPLASIA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

BARRETT ESOPHAGUS; COHORT STUDIES; DISEASE PROGRESSION; ESOPHAGUS; GREAT BRITAIN; HUMANS;

EID: 35448967106     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00733.x     Document Type: Article

References (69)

1. Haggitt R, Dean P. Adenocarcinoma in Barrett's epithelium. In: Spechler S, Goyal R, (eds). Barrett's Esophagus: Pathophysiology, Diagnosis, and Management. New York: Elsevier, 1985: 153-66.
2. Reid B, Levine D, Longton G, Blount P, Rabinovitch P. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000; 95: 1669-76.
3. Skinner D, Walther B, Riddell R, Schmidt H, Iascone C, Demeester T. Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg 1983; 198: 554-65.
4. Rosenberg J, Budev H, Edwards R, Singal S, Steiger Z, Sundareson A. Analysis of adenocarcinoma in Barrett's esophagus utilizing a staging system. Cancer 1985; 55: 1353-60.
5. Paraf F, Flejou J, Pignon J, Fekete F, Potet F. Surgical pathology of adenocarcinoma arising in Barrett's esophagus. Analysis of 67 cases. Am J Surg Pathol 1995; 19: 183-91.
6. Chalasani N, Wo J, Waring J. Racial differences in the histology, location and risk factors of esophageal cancer. J Clin Gastroenterol 1998; 26: 11-3.
7. Spechler S, Robbins A, Rubins H et al. Adenocarcinoma and Barrett's esophagus: An overrated risk? Gastroenterology 1984; 87: 927-33.
8. Iftikar S, James P, Steele R, Hardcastle J, Atkinson M. Length of Barrett's oesophagus: An important factor in the development of dysplasia and adenocarcinoma. Gut 1992; 33: 1155-8.
9. Solaymani-Dodaran M, Logan R, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004; 53: 1070-4.
10. Avidan B, Sonnenberg A, Schnell T, Chejfec G, Metz A, Sontag S. Hiatal hernia size, Barrett's length and severity of acid reflux are all risk factors for oesophageal adenocarcinoma. Am J Gastroenterol 2002; 97: 1930-6.
11. Csendes A, Smok G, Burdiles P et al. Prevalence of intestinal metaplasia according to the length of the specialized columnar epithelium lining the distal esophagus in patients with gastroesophageal reflux. Dis Esophagus 2003; 16: 24-8.
12. Gopal D, Lieberman D, Magaret N et al. Risk factors for dysplasia in patients with Barrett's esophagus (BE): Results from a multicentre consortium. Dig Dis Sci 2003; 48: 1537-41.
13. Rudolph R, Vaughan T, Storer B et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000; 132: 612-20.
14. Sagar P, Ackroyd R, Hosie K, Patterson J, Stoddard C, Kingsnorth A. Regression and progression of Barrett's oesophagus after antireflux surgery. Br J Surg 1995; 82: 806-10.
15. Parrilla P, Martinez de Haro L, Ortiz A et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2002; 237: 291-8.
16. Gore S, Healey C, Sutton R et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993; 7: 623-8.
17. Malesci A, Savarino V, Zentilin P et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omperazole. Gastrointest Endosc 1996; 44: 700-5.
18. Sharma P, Sampliner R, Camargo E. Normalisation of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92: 582-5.
19. Wilkinson S, Biddlestone L, Gore S, Shepherd N. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999; 13: 1205-9.
20. Brand D, Ylvisaker J, Gelfand M, Pope CI. Regression of columnar oesophageal (Barrett's) epithelium after antireflux surgery. N Engl J Med 1980; 302: 844-8.
21. Demeester S, Campos G, Demeester T et al. The impact of an antireflux procedure on intestinal metaplasia of the cardia. Ann Surg 1998; 228: 547-56.
22. Peters F, Ganesh S, Kuipers E et al. Endoscopic regression of Barrett's oesophagus during omperazole treatment; a randomised double blind study. Gut 1999; 45: 489-94.
23. Gurski R, Peters J, Hagen J et al. Barrett's esophagus can and does regress after antireflux surgery: A study of prevalence and predictive features. J Am Coll Surg 2003; 196: 706-13.
24. Mabrut J-Y, Baulieux J, Adham M et al. Impact of antireflux operation on columnar-lined esophagus. J Am Coll Surg 2003; 196: 60-7.
25. Oelschlager B, Barreca M, Chang L, Oleynikov D, Pellegrini C. Clinical and pathological response of Barrett's esophagus to laparoscopic antireflux surgery. Ann Surg 2003; 238: 458-66.
26. Ortiz A, Aguayo J, Parrilla P et al. [Barrett's esophagus does not revert after medical or surgical therapy for gastroesophageal reflux.] Rev Esp Enferm Dig 1991; 79: 89-94. (In Spanish.)
27. Srinivasan R, Katz P, Ramakrishnan A, Katzka D, Vela M, Castell D. Maximal acid reflux control for Barrett's esophagus: Feasible and effective. Aliment Pharmacol Ther 2001; 15: 519-24.
28. Neumann C, Iqbal T, Cooper B. Long term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment Pharmacol Ther 1995; 9: 451-4.
29. Kim S, Waring J, Spechler S et al. Diagnostic Inconsistencies in Barrett's esophagus. Gastroenterology 1994; 107: 945-9.
30. Dekel R, Wakelin D, Wendel C et al. Progression or regression of Barrett's esophagus - is it all in the eye of the beholder. Am J Gastroenterol 2003; 98: 2612-15.
31. Guda N, Partingdon S, Vakil N. Inter- and intra-observer variability in the measurement of length at endoscopy: Implications for the measurement of Barrett's esophagus. Gastrointest Endosc 2004; 59: 655-8.
32. Kim R, Baggott B, Rose S et al. Quantitative endoscopy: Precise computerized measurement of metaplastic epithelial surface area in Barrett's esophagus. Gastroenterology 1995; 108: 360-6.
33. Kim R, Rose S, Shar A, Weiner M, Reynolds J. Extent of Barrett's metaplasia: A prospective study of the serial change in area of Barrett's measured by quantitative endoscopic imaging. Gastrointes Endosc 1997; 45: 456-62.
34. Eisen G, Montgomery E, Azumi N et al. Qualitative mapping of Barrett's metaplasia: A prerequisite for intervention trials. Gastrointest Endosc 1999; 50: 814-18.
35. Cameron A, Lomboy C. Barrett's esophagus: Age, prevalence, extent columnar epithelium. Gastroenterol 1992; 103: 1241-5.
36. Nilsson J, Skobe V, Johansson J, Willen R, Johnsson F. Screening for oesophageal adenocarcinoma: An evaluation of a surveillance program for columnar metaplasia of the oesophagus. Scand J Gastroenterol 2000; 35: 10-16.
37. O'Connor J, Falk G, Richter J. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999; 94: 2037-42.
38. van der Veen A, Blankensteijn J, van Blankenstein M. Adenocarcinoma in Barrett's oesophagus: An overrated risk. Gut 1989; 30: 14-18.
39. Reed P, Watson A. Notes: UK National Barrett's Oesophagus Registry. Gut 1996; 39: 499-500.
40. Streitz J, Ellis F, Tilden R, Erickson R. Endoscopic surveillance of Barrett's esophagus: A cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol 1998; 93: 911-15.
41. Provenzale D, Schmitt C, Wong J. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94: 2043-53.
42. Eloubeidi M, Homan R, Martz M, Theobald K, Provenzale D. A cost analysis of outpatient care for patients with Barrett's esophagus in a managed care setting. Am J Gastroenterol 1999; 94: 2033-6.
43. Nietert P, Silverstein M, Makhashi M et al. Cost-effectiveness of screening a population with chronic gastroesophageal reflux. Gastrointest Endosc 2003; 57: 311-8.
44. Watson A. Barrett's oesophagus - 50 years on. Br J Surg 2000; 87: 529-31.
45. Schlemper R, Riddell R, Kato Y et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-5.
46. Bozymski E. Barrett's esophagus: Endoscopic characteristics. In: Spechler S, Goyal R, (eds). Barrett's Esophagus: Pathophysiology, Diagnosis and Management. New York: Elsevier, 1985: 113-20.
47. Spechler S, Goyal R. The columnar-lined esophagus, intestinal metaplasia and Norman Barrett. Gastroenterology 1996; 110: 614-21.
48. Barrett N. The lower esophagus lined by columnar epithelium. Surgery 1957; 41: 881-94.
49. Demeester S, Demeester T. Columnar mucosa and intestinal metaplasia of the esophagus: Fifty years controversy. Ann Surg 2000; 231: 303-21.
50. Weinstein W. Erosive esophagitis impairs accurate detection of Barrett's esophagus: A prospective randomized double blind study. Gastroenterology 1999; 116: A352.
51. Hanna S, Rastogi A, Weston AP et al. Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol 2006; 101: 1416-20.
52. Schnell T, Sontag S, Chejfec G. Adenocarcinomas arising in tongues or short segments of Barrett's esophagus. Dig Dis Sci 1992; 37: 137-43.
53. Sharma P, Morales T, Bhattacharyya A, Garewal H, Sampliner R. Squamous islands in Barrett's esophagus: What lies underneath? Am J Gastroenterol 1998; 93: 332-5.
54. Biddlestone L, Barham C, Wilkinson S, Barr H, Shepherd N. The histopathology of treated Barrett's esophagus: Squamous reepithelialization after acid suppression and photodynamic therapy. Am J Surg Pathol 1998; 22: 239-45.
55. Scott L, Sellin J. Letter. Aliment Pharmacol Ther 1994; 8: 473.
56. Csendes A, Smok G, Quiroz J et al. Clinical, endoscopic, and functional studies in 408 patients with Barrett's esophagus, compared to 174 cases with intestinal metaplasia of the cardia. Am J Gastroenterol 2002; 97: 554-60.
57. Lerut T, Coosemans W, van Raemdonck D et al. Surgical treatment of Barrett's carcinoma. Correlations between morphological findings and prognosis. J Thorac Cardiovasc Surg 1994; 107: 1059-65.
58. Cooper B, Neumann C, Cox M, Iqbal T. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998; 12: 893-7.
59. Sampliner R, The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97: 1888-95.
60. Bammer T, Hinder R, Klaus A, Trastek V, Achem S. Rationale for surgical therapy of Barrett's esophagus. Mayo Clinic Proc 2001; 76: 335-42.
61. Corey K, Schmitz S, Shaheen N. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A Meta-analalysis. Am J Gastroenterol 2003; 98: 2390-4.
62. McDonald M, Trastek V, Allen M, Deschamps C, Pairolero P. Barrett's esophagus: Does and antireflux procedure reduce the need for endoscopic surveillance. J Thorac Cardiovasc Surg 1996; 111: 1135-40.
63. Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998; 93: 536-41.
64. McCallum R, Polepalle S, Davenport K, Frierson H, Boyd S. Role of anti-reflux surgery against dysplasia in Barrett's esophagus. Gastroenterology 1991; 100 (Suppl): A121.
65. Ramus J, Gatenby P, Caygill C, Watson A. Endoscopic surveillance intervals for columnar-lined oesophagus (CLO) and impact on detection of dysplastic disease. Can J Gastroenterol 2005; 19 (Suppl C): R0090.
66. Cameron A, Carpenter H. Barrett's esophagus, high grade dysplasia and early adenocarcinoma: A pathological study. Am J Gastroenterol 1997; 4: 586-91.
67. Weston A, Krmpotich P, Cherian R, Dixon A, Topalovski M. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: Comparison with traditional long segment barrett's esophagus. Am J Gastroenterol 1997; 92: 407-13.
68. Padda S, Ramirez F. Accuracy in the diagnosis of short-segment Barrett's esophagus: The role of endoscopic experience. Gastrointest Endosc 2001; 54: 605-8.
69. Coad R, Shepherd N. Barrett's oesophagus: Definition, diagnosis and pathogenesis. Curr Diagn Pathol 2003; 9: 218-27.